![Lauren Brown: Another insightful article out of the AURORA collaboration](https://oncodaily.com/pub/uploads/2024/05/Screenshot-2024-05-09-at-11.37.45 PM-1280x506.jpeg)
Photo taken from www.clinical-lung-cancer.com
May 10, 2024, 14:58
Lauren Brown: Another insightful article out of the AURORA collaboration
Lauren Brown, PhD Candidate at Westmead Institute for Medical Research, University of Sydney & Medical Oncology Fellow at Westmead and Blacktown Hospitals, made the following post on X:
“Another insightful article out of the AURORA collaboration. Patients with KRAS, or PDL1 ≥50% are more likely to complete 24-months of pembro for NSCLC. Patients with oligoprogression in the brain treated with RT can still have enduring responses.”
Read the article.
Source: Lauren Brown/X
AURORA collaboration
Blacktown Hospital
brain metastases
cancer
cancer treatment
KRAS mutation
Lauren Brown
Medical Oncology Fellow
Medical Research
NSCLC
oligoprogression
OncoDaily
Oncology
PD-L1
pembrolizumab
PhD Candidate
radiotherapy
Research
University of Sydney
Westmead Hospital
Westmead Institute for Medical Research